You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新年喜訊第一彈!東曜藥業(01875.HK)生物藥研發被納入國家“重大新藥創制”科技重大專項 獲中央財政經費撥款
格隆匯 01-02 19:07

格隆匯獲悉,東曜藥業(01875.HK)於2020年1月2日宣佈,公司收到國家衞生健康委醫藥衞生科學發展研究中心下發的《關於重大新藥創制科技重大專項2019年度實施計劃立項課題的通知》(衞科專項函(2019)764號)。公司申請的“治療濕性黃斑病變的國家1類生物藥‘抗VEGF單克隆抗體(項目代號:TAB014)臨牀研究及產業化”專項課題,受到國家高度重視,被列入國家“重大新藥創制”科技重大專項,獲中央財政經費撥款。

“重大新藥創制”科技重大專項是《國家中長期科學和技術發展規劃綱要(2006-2020年)》頒佈的16個國家科技重大專項之一。國家科技重大專項是為了實現國家目標,通過核心技術突破和資源集成,在一定時限內完成的重大戰略產品、關鍵共性技術和重大工程,是中國科技發展的重中之重,16個科技重大專項涉及領域包括重大新藥創制、大型飛機、載人航天與探月工程等。

東曜藥業非常重視技術創新,近年積極加大研發投入力度。公司的新藥研發專項課題獲國家納入科技重大專項,足證國家對公司技術創新及TAB014單抗產品高度認可,也將有助於TAB014單抗項目開發和藥品上市的進程,加速造福廣大的患者。

公司在研的治療濕性黃斑病變的“抗VEGF單克隆抗體”(項目代號:TAB014),是一種基於貝伐珠單抗開發的眼用注射劑,用於視網膜新生血管的治療。目前TAB014單抗處於臨牀一期研究階段,項目進展順利,預期於2022年前完成臨牀III期研究,並於2023年推出市場。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account